Cite
The role of the CFP2C9-Leu 359allelic variant in the tolbutamide polymorphism
MLA
Sullivan-Klose, Theresa H., et al. “The Role of the CFP2C9-Leu 359allelic Variant in the Tolbutamide Polymorphism.” Pharmacogenetics, vol. 6, no. 4, Aug. 1996, pp. 341–49. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs48945163&authtype=sso&custid=ns315887.
APA
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996). The role of the CFP2C9-Leu 359allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6(4), 341–349.
Chicago
Sullivan-Klose, Theresa H., Burhan I. Ghanayem, Douglas A. Bell, Zhi-Yi Zhang, Laurence S. Kaminsky, Gillian M. Shenfleld, John O. Miners, Donald J. Birkett, and Joyce A. Goldstein. 1996. “The Role of the CFP2C9-Leu 359allelic Variant in the Tolbutamide Polymorphism.” Pharmacogenetics 6 (4): 341–49. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs48945163&authtype=sso&custid=ns315887.